[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=65ce15bbab5d6d9bbd81dfca7c84c4d2f0bfaf5d44326ede7356f5469bf1e5cd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741105860,
      "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "id": 132981498,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=65ce15bbab5d6d9bbd81dfca7c84c4d2f0bfaf5d44326ede7356f5469bf1e5cd"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Steps Into The Ring In The Obesity Drug Wars",
    "summary": "AbbVie Steps Into The Ring In The Obesity Drug Wars",
    "url": "https://finnhub.io/api/news?id=b52c8134dd4b27e7f296013c07218f5caa96377ce0c420d24e4daed48f627aa2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741089633,
      "headline": "AbbVie Steps Into The Ring In The Obesity Drug Wars",
      "id": 132976097,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b52c8134dd4b27e7f296013c07218f5caa96377ce0c420d24e4daed48f627aa2"
    }
  },
  {
    "ts": null,
    "headline": "SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease",
    "summary": "SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.1MONTREAL, March 4, 2025 /CNW/ - AbbVie  announced today...",
    "url": "https://finnhub.io/api/news?id=7c77389a16a1c870e30e883cf30659e160fd91bf2bed4773b92d82e63a86db87",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741075331,
      "headline": "SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease",
      "id": 132974476,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.1MONTREAL, March 4, 2025 /CNW/ - AbbVie  announced today...",
      "url": "https://finnhub.io/api/news?id=7c77389a16a1c870e30e883cf30659e160fd91bf2bed4773b92d82e63a86db87"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Present at the Leerink Partners Global Healthcare Conference",
    "summary": "NORTH CHICAGO, Ill., March 4, 2025 /PRNewswire/ -- AbbVie will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in a fireside...",
    "url": "https://finnhub.io/api/news?id=38b2fdd31626e0d3c9c0a64a54a130b3774dc084cb5ba0c2236da193f585575a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741075271,
      "headline": "AbbVie to Present at the Leerink Partners Global Healthcare Conference",
      "id": 132974466,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO, Ill., March 4, 2025 /PRNewswire/ -- AbbVie will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in a fireside...",
      "url": "https://finnhub.io/api/news?id=38b2fdd31626e0d3c9c0a64a54a130b3774dc084cb5ba0c2236da193f585575a"
    }
  }
]